MARLBOROUGH, Mass., April 11, 2024 /PRNewswire/ -- BTL Industries, Inc., a leading provider of innovative medical aesthetic solutions, petitioned the U.S. Patent Office to cancel all 58 claims of U.S. Patent No. 8,961,511 owned by the company InMode Ltd.
"We have strong reasons to believe InMode's patent claims are invalid," explained David Chmel, BTL's CEO, "and BTL has asked the United States Patent Office to initiate invalidation proceedings."
For more information about BTL and its medical solutions, please visit www.bodybybtl.com.
ABOUT BTL Founded in 1993, BTL has grown to become one of the world's leading medical and aesthetic equipment manufacturers. With over 3,500 employees in over 80 countries, BTL offers advanced non-invasive solutions for body-shaping, skin-tightening, and other medical aesthetic treatments, including women's intimate health and wellness. BTL's brands include EMSCULPT NEO®, EMFACE®, EMSCULPT®, EMSELLA®, EMTONE®, EMFEMME 360tm, EXIONtm, and Core to Floor®, as well as their proprietary HIFEM® and HIFEStm. Please visit www.bodybybtl.com for additional information.
Canopy Growth Corporation ("Canopy Growth" or the "Company") , today announced that on May 2, 2024, it entered into an exchange and subscription agreement (the "Agreement") with a single institutional investor (the "Investor") pursuant to which...
In a heartfelt message in the heart of spring, Kevin Guest, executive chairman at USANA Health Sciences , shares his insights and support for May's Family Wellness Month, an initiative that highlights the importance of family health and unity....
10 Barrel Brewing Co. ("10 Barrel Brewing Co." or "10 Barrel"), a Pacific Northwestern pioneer in craft brewing, a subsidiary of Tilray Brands, Inc. , unveils its latest creation: Pub Cerveza. Building upon the legacy of the ?Cheap Fun.' family,...
Fulgent Genetics, Inc. ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31,...
2seventy bio, Inc. will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET.
Participants can access the conference call live via webcast which will be available...
Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that new data supporting the utility of its DecisionDx-SCC test in patients with high-risk cutaneous squamous cell carcinoma (SCC)...
